ArticleNature cell biology2018
IL-1β inflammatory response driven by primary breast cancer prevents metastasis-initiating cell colonization.
Article in Nature cell biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 107 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
107 citing papers in PubMed, 2 syntheses or guidelines pooled it, 165 citations in OpenAlex.
- Prognostic prediction of systemic immune-inflammation index for patients with gynecological and breast cancers: a meta-analysis.World journal of surgical oncology · 2020Pooled it
- Locoregional therapy of the primary tumour in de novo stage IV breast cancer in 216 066 patients: A meta-analysis.Scientific reports · 2020Pooled it
- Article
- IL1R2 Deficiency Unleashes Neutrophil-Mediated Antitumor Potential in Sarcoma.Cancer immunology research · 2026Article
- A Literature Review of Interleukins in the Development and Treatment of Breast Cancer.International journal of molecular sciences · 2026Review
- Irradiated Tumor Cell-Derived Microparticles Activate Systemic Anti-Tumor Immunity via the STING/NLRP3/GSDMD Axis in Neutrophils.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- The role of growth hormone in metastasis and angiogenesis of breast cancer.Bioscience reports · 2026Review
- Locoregional Treatment in De Novo Bone-Only Metastatic Breast Cancer: Prospective, Multi-Institutional Real-World Data, BOMETIN, Protocol MF14-1a.Current oncology (Toronto, Ont.) · 2025Article
- The Diverse Roles of Mitochondria in Regulating Cancer Metastasis.Current issues in molecular biology · 2025Review
- Circulating tumor cells: Blood-based detection, molecular biology, and clinical applications.Cancer cell · 2025Review
- NF-κB in inflammation and cancer.Cellular & molecular immunology · 2025Review
- Targeting inflammasomes as an immunotherapeutic strategy for cancer.Journal of translational medicine · 2025Review
- Unveiling the link between chronic inflammation and cancer.Metabolism open · 2025Review
- Ferroptotic Neutrophils Induce Immunosuppression and Chemoresistance in Breast Cancer.Cancer research · 2025Article
- Targeting regulated cell death: Apoptosis, necroptosis, pyroptosis, ferroptosis, and cuproptosis in anticancer immunity.Journal of translational internal medicine · 2025Article
- Osteosarcoma biomarker analysis and drug targeting prediction based on pyroptosis-related genes.Medicine · 2025Article
- Cancer-induced systemic pre-conditioning of distant organs: building a niche for metastatic cells.Nature reviews. Cancer · 2024Review
- Review
- Article
- Increased prevalence of hybrid epithelial/mesenchymal state and enhanced phenotypic heterogeneity in basal breast cancer.iScience · 2024Article
47 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 7 institutions in 2 countries.
Funding
Abstract
Lack of insight into mechanisms governing breast cancer metastasis has precluded the development of curative therapies. Metastasis-initiating cancer cells (MICs) are uniquely equipped to establish metastases, causing recurrence and therapeutic resistance. Using various metastasis models, we discovered that certain primary tumours elicit a systemic inflammatory response involving interleukin-1β (IL-1β)-expressing innate immune cells that infiltrate distant MIC microenvironments. At the metastatic site, IL-1β maintains MICs in a ZEB1-positive differentiation state, preventing MICs from generating highly proliferative E-cadherin-positive progeny. Thus, when the inherent plasticity of MICs is impeded, overt metastases cannot be established. Ablation of the pro-inflammatory response or inhibition of the IL-1 receptor relieves the differentiation block and results in metastatic colonization. Among patients with lymph node-positive breast cancer, high primary tumour IL-1β expression is associated with better overall survival and distant metastasis-free survival. Our data reveal complex interactions that occur between primary tumours and disseminated MICs that could be exploited to improve patient survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.